The Role of the PGC1𝛼 Gly482Ser Polymorphism in Weight Gain due to Intensive Diabetes Therapy

Table 1

Candidate genes and SNPs analyzed for association with excess weight gain with intensive diabetes therapy. Genotyping was performed using ABI TaqMan assays with the indicated ABI identification numbers (custom, made to order). Minor allele frequencies are for Caucasian populations derived from published data and the SNP database (http://www.ncbi.nlm.nih.gov/SNP/). PPARG, peroxisome proliferator activated receptor γ; PPARGC1A, peroxisome proliferator-activated receptor γ coactivator-1α; HSD11B1, 11β-hydroxysteroid dehydrogenase 1; GR (NRC31), glucocorticoid receptor; GNB3, G protein β3 subunit; ADIPOQ, adiponectin; NPY, neuropeptide y, FTO (aliases KIAA1752, MGC5149), fat mass, and obesity-associated protein.

Gene	Chromosomal location	NCBI refSNP number	TaqMan ABI assay ID	Polymorphism	Minor allele frequency
PPARγ2	3p25	rs1801282	1129864	Pro12Ala (exon 1)	0.10
PPARGC1A	4p15.1	rs8192678	Custom 1643184	Gly482Ser T/C (5′ UTR)	0.34
		rs2279525			0.31
11-β HSD1	1q32	rs2884090	2502457	C/T; intron 4	0.21
GR (NRC31)	5q34	rs6188	1046353	G/T; intron 5	0.31
		rs11749561	178285	T/C; intron 3
GNB3	12p13	rs5443	2184734	C825T Silent/AS	0.30
ADIPOQ	3q27	rs266729	Custom 2412786	C-377G; promoter	0.29
NPY	7p15.1	rs5573	11164468	Ser22Ser	0.44
FTO	16q12.2	rs9939609	Custom 30090620	T to A in 3′ UTR	0.43